Immunogenicity of long-lasting recombinant factor VIII products
| Autor: | Sébastien Lacroix-Desmazes, Bernard Maillere, Maud Teyssandier, Mathieu Ing, Marc Pallardy, Sandrine Delignat, Nimesh Gupta |
|---|---|
| Přispěvatelé: | HAL-UPMC, Gestionnaire, Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute of Immunology, Institut de Biologie et de Technologies de Saclay (IBITECS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Faculté de Pharmacie, Université Paris-Sud - Paris 11 (UP11), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de Biologie et de Technologies de Saclay ( IBITECS ), Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Université Paris-Sud - Paris 11 ( UP11 ) |
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Long lasting congenital hereditary and neonatal diseases and abnormalities [SDV.IMM] Life Sciences [q-bio]/Immunology Fc fusion Recombinant Fusion Proteins Immunology 030204 cardiovascular system & hematology Hemophilia A Recombinant factor viii 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases [ SDV.IMM ] Life Sciences [q-bio]/Immunology Medicine Humans Hemophilia Factor VIII biology business.industry Immunogenicity PEGylation 3. Good health 030104 developmental biology Coagulation Long-lasting Coagulation factor biology.protein [SDV.IMM]Life Sciences [q-bio]/Immunology Antibody business Albumin fusion Fc fragment Half-Life |
| Zdroj: | Cellular Immunology Cellular Immunology, Elsevier, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩ Cellular Immunology, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩ Cellular Immunology, Elsevier, 2016, 301, pp.40-48. 〈10.1016/j.cellimm.2015.12.006〉 |
| ISSN: | 1090-2163 0008-8749 |
| Popis: | International audience; Replacement therapy for patients with hemophilia A using plasma-derived or recombinant factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the occurrence of neutralizing antibodies in a substantial number of patients. In the recent years, enormous efforts have been invested to develop new generations of coagulation factors with extended half-lives. Presumably, the use of long-lasting FVIII products should reduce the frequency of administration to the patients and drastically improve their quality of life. The question of their immunogenicity remains however unanswered as yet. The present review proposes a summary of the different strategies developed to enhance the half-life of FVIII, including fusion of FVIII to the Fc fragment of the human IgG1 or to human serum albumin, or attachment of polyethylene glycol. Based on the available literature, we hypothesize on the potential benefits or risks associated with each of the latter strategies in terms of immunogenicity of the newly derived hemostatic drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect